Tag Archives: biomarkers

fight-crc-lisa-fund-awards-2014

7th Lisa Fund Grant Awarded to Dr. Ho-Chou Tu

7th Lisa Fund Grant Awarded to Dr. Ho-Chou Tu

Fight Colorectal Cancer is excited to announce that Dr. Ho-Chou Tu received our 7th Lisa Fund Fellowship Grant – a $50,000 award given to a late-stage colorectal cancer researcher. This award is distributed through the Lisa Fund in partnership with American Association of Cancer Research (AACR.) Dr. Tu is a research fellow at the Children’s Hospital in Boston. She plans to use the award to determine the relationship between the Lin28A/B gene and colon cancer progression and prognosis. She hopes that her research will lead to predictive biomarkers for prognosis of colon cancer and a potential therapeutic target aimed to reduce colon cancer progression. Dr. Tu, a native of Taiwan,

Personalizing Personalized Medicine

On Monday, April 25th, Fight Colorectal Cancer held a free patient webinar that tackled the somewhat complex but fascinating topic of personalized medicine. Personalized medicine is what the cancer community calls treatments that are tailored to each patient’s genetic makeup. It is the future of cancer care and in some cases, it is already making a big difference in the ways patients are treated. You can learn about these cutting edge treatments and about emerging findings in an archive of the webinar below. Our thanks to Carolyn Grande, CRNP, AOCNP for leading the discussion. She a phenomenal educator on this topic and a member of our Medical Advisory Board. She graciously

Upcoming Patient Webinars Will Bring the Science to YOU

Fight Colorectal Cancer is giving you the opportunity to talk to researchers and medical professionals in April and May through online webinars designed to bring the science of treating colorectal cancer down to the personal. The latest news from the petri dish Wednesday, April 20, 2011 8 – 9 PM Eastern Dr. Rona Yaeger will discuss the research she has been conducting over the past year with the grant she received as part of Fight Colorectal Cancer’s Lisa Fund research program. Dr. Yaeger’s research focused on inhibiting the AKT pathway in colorectal cancer cells. She conducted basic research to determine how inhibitors to the pathway might affect cells of patients

Commercial Test for BRAF Gene Available

Clarient Inc. announced the launch of a commercially available test for the BRAF mutation in colorectal cancer.  The test detects mutations in colorectal cancer tumor tissue. In a recent study, patients with mutated BRAF did not respond to treatment with two drugs that block epidermal growth factor receptors (EGFR) — Erbitux® (cetuximab) and Vectibix™ (panitumumab).  Patients in the study all had normal, wild-type KRAS, another mutation that blocks response to Erbitux and Vectibix.

Top